603538 美诺华
已收盘 01-09 15:00:00
资讯
新帖
简况
美诺华（603538）披露“美诺转债”2026年付息公告，1月7日股价上涨0.89%
证券之星 · 01-07 22:43
美诺华（603538）披露“美诺转债”2026年付息公告，1月7日股价上涨0.89%
1月5日美诺华涨5.15%，新华策略精选股票A基金重仓该股
证券之星 · 01-05
1月5日美诺华涨5.15%，新华策略精选股票A基金重仓该股
每周股票复盘：美诺华（603538）使用1000万闲置募资购大额存单
证券之星 · 01-02
每周股票复盘：美诺华（603538）使用1000万闲置募资购大额存单
美诺华（603538）披露使用闲置募集资金进行现金管理进展公告，12月30日股价上涨0.1%
证券之星 · 2025-12-30
美诺华（603538）披露使用闲置募集资金进行现金管理进展公告，12月30日股价上涨0.1%
每周股票复盘：美诺华（603538）决定不向下修正转股价格
证券之星 · 2025-12-28
每周股票复盘：美诺华（603538）决定不向下修正转股价格
美诺华：第五届董事会第二十二次会议决议
证券日报 · 2025-12-24
美诺华：第五届董事会第二十二次会议决议
美诺华(603538.SH)子公司阿托伐他汀钙原料药通过CDE技术审评
智通财经 · 2025-12-18
美诺华(603538.SH)子公司阿托伐他汀钙原料药通过CDE技术审评
美诺华（603538）披露“美诺转债”预计满足转股价格向下修正条件的提示性公告，12月17日股价上涨0.05%
证券之星 · 2025-12-17
美诺华（603538）披露“美诺转债”预计满足转股价格向下修正条件的提示性公告，12月17日股价上涨0.05%
美诺华(603538.SH)子公司获得非布司他片药品注册证书
智通财经 · 2025-12-10
美诺华(603538.SH)子公司获得非布司他片药品注册证书
美诺华（603538）公司公告不向下修正“美诺转债”转股价格，12月03日股价上涨2.16%
证券之星 · 2025-12-03
美诺华（603538）公司公告不向下修正“美诺转债”转股价格，12月03日股价上涨2.16%
美诺华（603538）披露2021年股票期权与限制性股票激励计划预留授予第二个行权期自主行权结果暨股份变动公告，11月25日股价上涨2.25%
证券之星 · 2025-11-25
美诺华（603538）披露2021年股票期权与限制性股票激励计划预留授予第二个行权期自主行权结果暨股份变动公告，11月25日股价上涨2.25%
每周股票复盘：美诺华（603538）将召开2025年第三季度业绩说明会
证券之星 · 2025-11-23
每周股票复盘：美诺华（603538）将召开2025年第三季度业绩说明会
美诺华（603538）披露召开2025年第三季度业绩说明会，11月19日股价下跌3.6%
证券之星 · 2025-11-19
美诺华（603538）披露召开2025年第三季度业绩说明会，11月19日股价下跌3.6%
每周股票复盘：美诺华（603538）决定不向下修正转股价格
证券之星 · 2025-11-16
每周股票复盘：美诺华（603538）决定不向下修正转股价格
美诺华（603538）公司公告不向下修正“美诺转债”转股价格，11月12日股价下跌1.56%
证券之星 · 2025-11-12
美诺华（603538）公司公告不向下修正“美诺转债”转股价格，11月12日股价下跌1.56%
每周股票复盘：美诺华（603538）美诺转债或触向下修正条件
证券之星 · 2025-11-09
每周股票复盘：美诺华（603538）美诺转债或触向下修正条件
美诺华（603538）披露关于“美诺转债”预计满足转股价格向下修正条件的提示性公告，11月05日股价下跌0.87%
证券之星 · 2025-11-05
美诺华（603538）披露关于“美诺转债”预计满足转股价格向下修正条件的提示性公告，11月05日股价下跌0.87%
每周股票复盘：美诺华（603538）Q3净利增5.78%，制剂业务放量
证券之星 · 2025-11-02
每周股票复盘：美诺华（603538）Q3净利增5.78%，制剂业务放量
美诺华：10月28日接受机构调研，上海景林资产管理有限公司、创金合信基金管理有限公司等多家机构参与
证券之星 · 2025-10-29
美诺华：10月28日接受机构调研，上海景林资产管理有限公司、创金合信基金管理有限公司等多家机构参与
美诺华（603538）2025年三季报简析：营收净利润同比双双增长，应收账款上升
证券之星 · 2025-10-29
美诺华（603538）2025年三季报简析：营收净利润同比双双增长，应收账款上升
公司概况
公司名称：
宁波美诺华药业股份有限公司
所属行业：
医药制造业
上市日期：
2017-04-07
主营业务：
宁波美诺华药业股份有限公司的主营业务是特色原料药（包括中间体，下同）和制剂研发、生产与销售。公司的主要产品是缬沙坦、氯沙坦、培哚普利叔丁胺片、瑞舒伐他汀钙、阿托伐他汀钙、普瑞巴林、阿哌沙班片、异烟肼片。
发行价格：
14.03
{"stockData":{"symbol":"603538","market":"SH","secType":"STK","nameCN":"美诺华","latestPrice":21.1,"timestamp":1767942001000,"preClose":20.98,"halted":0,"volume":7148673,"delay":0,"changeRate":0.0057,"floatShares":216000000,"shares":221000000,"eps":0.4509,"marketStatus":"已收盘","change":0.12,"latestTime":"01-09 15:00:00","open":20.97,"high":21.14,"low":20.68,"amount":149000000,"amplitude":0.0219,"askPrice":21.11,"askSize":62,"bidPrice":21.1,"bidSize":4,"shortable":0,"etf":0,"ttmEps":0.4509,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768181400000},"marketStatusCode":5,"adr":0,"adjPreClose":20.98,"symbolType":"stock","openAndCloseTimeList":[[1767922200000,1767929400000],[1767934800000,1767942000000]],"highLimit":23.08,"lowLimit":18.88,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":220630759,"isCdr":false,"pbRate":2.07,"roa":"--","peRate":46.795298,"roe":"4.26%","epsLYR":0.31,"committee":-0.436426,"marketValue":4655000000,"turnoverRate":0.0331,"status":0,"floatMarketCap":4562000000},"requestUrl":"/m/hq/s/603538/wiki","defaultTab":"wiki","newsList":[{"id":"2601801788","title":"美诺华（603538）披露“美诺转债”2026年付息公告，1月7日股价上涨0.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601801788","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601801788?lang=zh_cn&edition=full","pubTime":"2026-01-07 22:43","pubTimestamp":1767796989,"startTime":"0","endTime":"0","summary":"截至2026年1月7日收盘，美诺华报收于20.48元，较前一交易日上涨0.89%，最新总市值为45.19亿元。该股当日开盘20.29元，最高20.75元，最低20.26元，成交额达1.29亿元，换手率为2.91%。公司近日发布公告称，宁波美诺华药业股份有限公司于2021年1月14日发行的可转换公司债券将于2026年1月14日支付第五年利息，计息期间为2025年1月14日至2026年1月13日，票面利率1.8%，每张兑息1.80元（含税）。兑息对象为登记在册的全体可转债持有人。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010700039232.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603538"],"gpt_icon":0},{"id":"2601300518","title":"1月5日美诺华涨5.15%，新华策略精选股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2601300518","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601300518?lang=zh_cn&edition=full","pubTime":"2026-01-05 15:33","pubTimestamp":1767598427,"startTime":"0","endTime":"0","summary":"证券之星消息，1月5日美诺华涨5.15%，收盘报20.23元，换手率4.22%，成交量9.12万手，成交额1.83亿元。重仓美诺华的公募基金请见下表：该股最近90天内共有3家机构给出评级，买入评级2家，增持评级1家；过去90天内机构目标均价为26.04。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共5家，其中持有数量最多的公募基金为新华基金的新华策略精选股票A。该公募基金现任基金经理为赵强。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500015400.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603538","BK0239"],"gpt_icon":0},{"id":"2600035086","title":"每周股票复盘：美诺华（603538）使用1000万闲置募资购大额存单","url":"https://stock-news.laohu8.com/highlight/detail?id=2600035086","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600035086?lang=zh_cn&edition=full","pubTime":"2026-01-02 02:15","pubTimestamp":1767291312,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，美诺华报收于19.69元，较上周的19.9元下跌1.06%。本周，美诺华12月22日盘中最高价报19.96元。公司公告汇总宁波美诺华药业股份有限公司于2025年12月30日使用闲置可转债募集资金1,000万元购买招商银行单位大额存单2025年第5834期，产品期限3年，年化收益率1.75%，为固定利率型存款产品，允许提前转让。本次行权后总股本由220,630,566股增至220,630,759股，实际控制人未发生变化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010200000520.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603538","BK0239"],"gpt_icon":0},{"id":"2595187877","title":"美诺华（603538）披露使用闲置募集资金进行现金管理进展公告，12月30日股价上涨0.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595187877","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595187877?lang=zh_cn&edition=full","pubTime":"2025-12-30 22:33","pubTimestamp":1767105195,"startTime":"0","endTime":"0","summary":"截至2025年12月30日收盘，美诺华报收于19.48元，较前一交易日上涨0.1%，最新总市值为42.98亿元。该股当日开盘19.37元，最高19.52元，最低19.26元，成交额达6283.99万元，换手率为1.5%。公司近日发布公告称，宁波美诺华药业股份有限公司于2025年12月30日使用闲置可转债募集资金1,000万元购买招商银行单位大额存单2025年第5834期，产品期限3年，年化收益率1.75%，为固定利率型存款产品，允许提前转让。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123000044441.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603538","BK0239"],"gpt_icon":0},{"id":"2594420592","title":"每周股票复盘：美诺华（603538）决定不向下修正转股价格","url":"https://stock-news.laohu8.com/highlight/detail?id=2594420592","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594420592?lang=zh_cn&edition=full","pubTime":"2025-12-28 04:34","pubTimestamp":1766867651,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，美诺华报收于19.69元，较上周的19.9元下跌1.06%。本周，美诺华12月22日盘中最高价报19.96元。本周关注点公司公告汇总：美诺华决定不向下修正“美诺转债”转股价格。公司公告汇总宁波美诺华药业股份有限公司于2025年12月24日召开第五届董事会第二十二次会议，审议通过《关于不向下修正可转换公司债券转股价格的议案》，表决结果为同意5票，反对0票，弃权0票，议案获全票通过。公司董事会决定本次不向下修正转股价格。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800001166.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603538"],"gpt_icon":0},{"id":"2593744254","title":"美诺华：第五届董事会第二十二次会议决议","url":"https://stock-news.laohu8.com/highlight/detail?id=2593744254","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593744254?lang=zh_cn&edition=full","pubTime":"2025-12-24 19:38","pubTimestamp":1766576280,"startTime":"0","endTime":"0","summary":"证券日报网讯 12月24日，美诺华（维权）发布公告称，公司第五届董事会第二十二次会议审议通过《关于不向下修正可转换公司债券转股价格的议案》。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-24/doc-inhcxcti4388392.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-24/doc-inhcxcti4388392.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["603538","BK0239"],"gpt_icon":0},{"id":"2592973572","title":"美诺华(603538.SH)子公司阿托伐他汀钙原料药通过CDE技术审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2592973572","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592973572?lang=zh_cn&edition=full","pubTime":"2025-12-18 15:56","pubTimestamp":1766044573,"startTime":"0","endTime":"0","summary":"智通财经APP讯，美诺华(603538.SH)发布公告，近日，公司控股子公司宣城美诺华药业有限公司(简称“宣城美诺华”)收到国家药品监督管理局核准签发的阿托伐他汀钙原料药《化学原料药上市申请批准通知书》。宣城美诺华的阿托伐他汀钙原料药通过CDE技术审评，证明该原料药已符合国家相关药品审评技术标准，可销售至国内市场，将进一步丰富子公司的产品线，有助于拓展公司业务领域，有利于进一步扩展公司原料药制剂一体化生产范围，增强公司一体化生产的优势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1383068.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CDE","LU1223082519.USD","BK4017","603538","BK0239","LU1223083913.SGD","LU1223082196.USD"],"gpt_icon":0},{"id":"2592915851","title":"美诺华（603538）披露“美诺转债”预计满足转股价格向下修正条件的提示性公告，12月17日股价上涨0.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592915851","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592915851?lang=zh_cn&edition=full","pubTime":"2025-12-17 22:10","pubTimestamp":1765980647,"startTime":"0","endTime":"0","summary":"截至2025年12月17日收盘，美诺华报收于19.4元，较前一交易日上涨0.05%，最新总市值为42.8亿元。该股当日开盘19.39元，最高19.46元，最低18.97元，成交额达7173.35万元，换手率为1.72%。公司近日发布公告，提示“美诺转债”可能触发转股价格向下修正条件。截至2025年12月17日，已有连续十个交易日公司股票收盘价低于当期转股价格25.68元/股的90%，即23.11元/股。公司将在触发条件当日召开董事会审议是否修正转股价格，并及时履行信息披露义务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121700039288.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603538"],"gpt_icon":0},{"id":"2590006153","title":"美诺华(603538.SH)子公司获得非布司他片药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2590006153","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590006153?lang=zh_cn&edition=full","pubTime":"2025-12-10 17:04","pubTimestamp":1765357451,"startTime":"0","endTime":"0","summary":"智通财经APP讯，美诺华(603538.SH)发布公告，公司全资子公司宁波美诺华天康药业有限公司(以下简称“美诺华天康”)于近日收到国家药品监督管理局(以下简称“国家药监局”)核准签发的非布司他片《药品注册证书》。药品适应症：适用于痛风患者高尿酸血症的长期治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379885.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"美诺华(603538.SH)子公司获得非布司他片药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","603538"],"gpt_icon":0},{"id":"2588104495","title":"美诺华（603538）公司公告不向下修正“美诺转债”转股价格，12月03日股价上涨2.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588104495","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588104495?lang=zh_cn&edition=full","pubTime":"2025-12-03 22:08","pubTimestamp":1764770906,"startTime":"0","endTime":"0","summary":"截至2025年12月3日收盘，美诺华报收于20.3元，较前一交易日上涨2.16%，最新总市值为44.79亿元。该股当日开盘19.8元，最高20.3元，最低19.74元，成交额达7946.59万元，换手率为1.84%。公司于2025年12月3日召开第五届董事会第二十次会议，审议通过不向下修正转股价格的议案，决定本次不向下修正转股价格。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120300040076.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603538"],"gpt_icon":0},{"id":"2586794934","title":"美诺华（603538）披露2021年股票期权与限制性股票激励计划预留授予第二个行权期自主行权结果暨股份变动公告，11月25日股价上涨2.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586794934","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586794934?lang=zh_cn&edition=full","pubTime":"2025-11-25 22:10","pubTimestamp":1764079850,"startTime":"0","endTime":"0","summary":"截至2025年11月25日收盘，美诺华报收于19.97元，较前一交易日上涨2.25%，最新总市值为44.06亿元。近日，宁波美诺华药业股份有限公司发布关于2021年股票期权与限制性股票激励计划预留授予第二个行权期自主行权结果暨股份变动的公告。公告显示，本次可行权股票期权数量为738,491股，行权期间为2024年12月25日至2025年11月24日。截至2025年11月24日，累计行权278,530股，占可行权总量的37.72%。行权方式为自主行权，行权所得股票于行权日后的第二个交易日上市交易。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112500038777.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603538","BK0239"],"gpt_icon":0},{"id":"2585108731","title":"每周股票复盘：美诺华（603538）将召开2025年第三季度业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2585108731","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585108731?lang=zh_cn&edition=full","pubTime":"2025-11-23 01:50","pubTimestamp":1763833822,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘，美诺华报收于19.36元，较上周的22.11元下跌12.44%。本周，美诺华11月17日盘中最高价报22.8元。美诺华当前最新总市值42.71亿元，在化学制药板块市值排名114/151，在两市A股市值排名3626/5167。公司董事长兼总经理姚成志、董事会秘书兼财务负责人应高峰及独立董事贝洪俊将出席。说明会主要内容包括公司2025年第三季度经营成果、财务状况等投资者关注的问题。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112300000328.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603538","BK0239"],"gpt_icon":0},{"id":"2584794215","title":"美诺华（603538）披露召开2025年第三季度业绩说明会，11月19日股价下跌3.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584794215","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584794215?lang=zh_cn&edition=full","pubTime":"2025-11-19 22:09","pubTimestamp":1763561360,"startTime":"0","endTime":"0","summary":"截至2025年11月19日收盘，美诺华报收于20.37元，较前一交易日下跌3.6%，最新总市值为44.94亿元。该股当日开盘21.1元，最高21.27元，最低20.31元，成交额达1.51亿元，换手率为3.38%。公司近日发布公告称，宁波美诺华药业股份有限公司将于2025年11月27日13:00-14:45通过上海证券交易所上证路演中心举行2025年第三季度业绩说明会，以视频直播和网络互动方式召开。说明会主要内容包括公司2025年第三季度经营成果、财务状况等投资者关注的问题。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111900039705.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603538","BK0239"],"gpt_icon":0},{"id":"2583659726","title":"每周股票复盘：美诺华（603538）决定不向下修正转股价格","url":"https://stock-news.laohu8.com/highlight/detail?id=2583659726","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583659726?lang=zh_cn&edition=full","pubTime":"2025-11-16 02:55","pubTimestamp":1763232910,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，美诺华报收于22.11元，较上周的22.08元上涨0.14%。因公司股票已满足“美诺转债”转股价格向下修正条件，董事会决定不向下修正转股价格。增资完成后，宣城美诺华注册资本由196,078,500元增至384,467,647.06元，公司持股比例由100%变更为51%，安徽美诺华持股49%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600000650.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603538"],"gpt_icon":0},{"id":"2582607377","title":"美诺华（603538）公司公告不向下修正“美诺转债”转股价格，11月12日股价下跌1.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582607377","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582607377?lang=zh_cn&edition=full","pubTime":"2025-11-12 22:23","pubTimestamp":1762957402,"startTime":"0","endTime":"0","summary":"截至2025年11月12日收盘，美诺华报收于21.45元，较前一交易日下跌1.56%，最新总市值为47.32亿元。该股当日开盘21.8元，最高21.96元，最低21.27元，成交额达1.4亿元，换手率为2.99%。根据近日发布的公告，宁波美诺华药业股份有限公司于2025年11月12日召开第五届董事会第十九次会议，审议通过《关于不向下修正可转换公司债券转股价格的议案》。董事会决定本次不向下修正转股价格。下一触发修正条款的期间自2025年11月13日起重新计算。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111200041365.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603538","BK0239"],"gpt_icon":0},{"id":"2582618258","title":"每周股票复盘：美诺华（603538）美诺转债或触向下修正条件","url":"https://stock-news.laohu8.com/highlight/detail?id=2582618258","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582618258?lang=zh_cn&edition=full","pubTime":"2025-11-09 03:30","pubTimestamp":1762630238,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘，美诺华报收于22.08元，较上周的23.83元下跌7.34%。本周，美诺华11月3日盘中最高价报23.99元。本周关注点公司公告汇总：截至2025年11月5日，“美诺转债”已有10个交易日收盘价低于转股价格25.68元/股的90%，预计可能触发转股价格向下修正条款。公司公告汇总宁波美诺华药业股份有限公司发布关于“美诺转债”预计满足转股价格向下修正条件的提示性公告。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110900001281.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603538","BK0239"],"gpt_icon":0},{"id":"2581775463","title":"美诺华（603538）披露关于“美诺转债”预计满足转股价格向下修正条件的提示性公告，11月05日股价下跌0.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581775463","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581775463?lang=zh_cn&edition=full","pubTime":"2025-11-05 22:15","pubTimestamp":1762352125,"startTime":"0","endTime":"0","summary":"截至2025年11月5日收盘，美诺华报收于22.78元，较前一交易日下跌0.87%，最新总市值为50.26亿元。公司近日发布关于“美诺转债”预计满足转股价格向下修正条件的提示性公告。若在任意连续三十个交易日内有至少十五个交易日收盘价低于该阈值，将触发转股价格向下修正条款。公司董事会将在条件触发后审议是否修正转股价格，并及时履行信息披露义务。修正方案须经股东大会表决，出席会议股东所持表决权三分之二以上通过方可实施。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110500040614.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603538","BK0239"],"gpt_icon":0},{"id":"2580475888","title":"每周股票复盘：美诺华（603538）Q3净利增5.78%，制剂业务放量","url":"https://stock-news.laohu8.com/highlight/detail?id=2580475888","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580475888?lang=zh_cn&edition=full","pubTime":"2025-11-02 02:37","pubTimestamp":1762022229,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘，美诺华报收于23.83元，较上周的21.83元上涨9.16%。本周，美诺华10月31日盘中最高价报24.0元。股本股东变化截至2025年9月30日，公司股东户数为3.47万户，较6月30日增加2336.0户，增幅7.22%。其中第三季度单季度主营收入4.39亿元，同比上升28.8%；单季度归母净利润4687.02万元，同比上升5.78%；单季度扣非净利润4960.71万元，同比上升51.29%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200000422.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603538","BK0239"],"gpt_icon":0},{"id":"2579908474","title":"美诺华：10月28日接受机构调研，上海景林资产管理有限公司、创金合信基金管理有限公司等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2579908474","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579908474?lang=zh_cn&edition=full","pubTime":"2025-10-29 19:58","pubTimestamp":1761739128,"startTime":"0","endTime":"0","summary":"mRN药物合作开发方面，公司在CDMO前端合作持续进行，目前处于前期阶段。生产计划严格根据订单情况安排，合理利用产能，有利于降低单位产品所分摊的各项费用，实现了成本优化。PI方面，目前价格处于底部，公司出货量有增量但因价格变化整体保持平稳，预计今年价格保持平稳、量增状态，明后年排除涨价因素出货量仍将保持增长。创新药及创新类大健康产品是布局核心，包括JH389项目及其他创新药合作。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102900040807.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09983","603538","BK1258","BK0239","BK1542","BK1583","BK1229"],"gpt_icon":0},{"id":"2579913737","title":"美诺华（603538）2025年三季报简析：营收净利润同比双双增长，应收账款上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2579913737","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579913737?lang=zh_cn&edition=full","pubTime":"2025-10-29 06:13","pubTimestamp":1761689583,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期美诺华发布2025年三季报。截至本报告期末，公司营业总收入11.17亿元，同比上升17.67%，归母净利润9592.54万元，同比上升51.66%。按单季度数据看，第三季度营业总收入4.39亿元，同比上升28.8%，第三季度归母净利润4687.02万元，同比上升5.78%。本报告期美诺华应收账款上升，应收账款同比增幅达46.92%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102900008647.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603538"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1767966576714,"stockEarnings":[{"period":"1week","weight":0.0904},{"period":"1month","weight":0.0407},{"period":"3month","weight":-0.0507},{"period":"6month","weight":-0.091},{"period":"1year","weight":0.6919},{"period":"ytd","weight":0.0904}],"compareEarnings":[{"period":"1week","weight":0.0288},{"period":"1month","weight":0.0444},{"period":"3month","weight":0.0477},{"period":"6month","weight":0.1632},{"period":"1year","weight":0.264},{"period":"ytd","weight":0.0288}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"宁波美诺华药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"34704人(较上一季度增加7.22%)","perCapita":"6229股","listingDate":"2017-04-07","address":"浙江省宁波市鄞州区高新区扬帆路999弄1号1406室","registeredCapital":"22063万元","survey":" 宁波美诺华药业股份有限公司的主营业务是特色原料药（包括中间体，下同）和制剂研发、生产与销售。公司的主要产品是缬沙坦、氯沙坦、培哚普利叔丁胺片、瑞舒伐他汀钙、阿托伐他汀钙、普瑞巴林、阿哌沙班片、异烟肼片。","listedPrice":14.03},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"美诺华(603538)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供美诺华(603538)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"美诺华,603538,美诺华股票,美诺华股票老虎,美诺华股票老虎国际,美诺华行情,美诺华股票行情,美诺华股价,美诺华股市,美诺华股票价格,美诺华股票交易,美诺华股票购买,美诺华股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"美诺华(603538)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供美诺华(603538)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}